share_log

BRIEF-Arcus Biosciences Says Dosed First Subject In ARC-10

路透社 ·  Mar 17, 2021 05:04
March 16 (Reuters) - Arcus Biosciences Inc :
   * ARCUS BIOSCIENCES INC - HAS DOSED FIRST SUBJECT IN ARC-10, A PHASE 3 STUDY
   * ARCUS BIOSCIENCES - DOSING OF FIRST SUBJECT TRIGGERS MILESTONE PAYMENTS TO WUXI BIOLOGICS OF $10 MILLION AND ABMUNO THERAPEUTICS OF $5 MILLION
   * ARCUS BIOSCIENCES INC - WILL OWE A SUBSEQUENT MILESTONE PAYMENT UPON INITIATION OF A PHASE 3 TRIAL IN A SECOND INDICATION

Source text: () Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment